| Literature DB >> 22696166 |
Abstract
Despite massive efforts, proteomics has not delivered biomarkers of clinical value. However, the technologies that are emerging today have the power to reach deep into proteomes and identify the patterns associated with different diseases. Study design is then crucial and sample quality, bioinformatics approaches, prevalidation, using independent patient cohort need to attract increased attention before proteomics will contribute to the needs of personalized medicine.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22696166 DOI: 10.1002/prca.201200020
Source DB: PubMed Journal: Proteomics Clin Appl ISSN: 1862-8346 Impact factor: 3.494